DoW Reconstructive Transplant, Investigator-Initiated Research Award
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The fiscal year 2026 Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award, solicitation number HT9425256RTRPIIRA, is a funding opportunity issued by the Defense Health Agency to support research advancing vascularized composite allotransplantation (VCA). The program targets the improvement of access, safety, and quality of life for catastrophically injured Service Members, Veterans, and the general public. Eligible projects may span from basic to translational research, including preclinical animal models and clinical research in human subjects, though clinical trials are explicitly excluded. Awards are capped at 1.0 million dollars with a maximum period of performance of three years. Applicants must demonstrate military relevance and address at least one FY26 RTRP Focus Area, providing preliminary or published data to support their scientific rationale. The application process requires active registration in SAM.gov, eBRAP, and Grants.gov, with a pre-application deadline of October 21, 2026, and a full application deadline of November 4, 2026. Selection is based on a two-tier review process consisting of a technical peer review and a programmatic review. Required documentation includes a project narrative, statement of work, impact statement, and military relevance document, among other technical attachments. All key personnel must disclose foreign affiliations in accordance with National Security Presidential Memorandum-33.
General Info
Place of Performance
Not specifiedSet-Aside
Timeline
Anticipated deadline
Organization & Contact Information
Full Description
Summary: The fiscal year 2026 (FY26) Reconstructive Transplant Research Program (RTRP) Investigator-Initiated Research Award supports studies that have the potential to make an important contribution to reconstructive transplant research, patient care, and/or quality of life. All projects must demonstrate solid scientific rationale with military-relevant utility. The Investigator-Initiated Research Award does not support clinical trials.
Distinctive Features:
· Scope: Applications may focus on any phase of research from basic through translational, including preclinical studies in animal models, and clinical research in human subjects or human anatomical substances.
· Study Design and Feasibility: The study design should be rigorous and support maximal reproducibility and translational feasibility. A strong statistical plan with appropriate power analysis is important.
· Impact: Project results should have the potential for long- and short-term impact on the reconstructive transplant research field and/or patient community. Projects should address at least one of the FY26 RTRP Focus Areas.
· Preliminary Data: Preliminary and/or published data that are relevant to reconstructive transplantation and support the rationale for the proposed research must be included.
· Military Relevance: All projects must be responsive to the health care needs of military Service Members and/or Veterans recovering from traumatic injury, and/or their Family members, caregivers, or clinicians, as well as the general public. Collaboration with military researchers and clinicians is encouraged but not required.
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Defense → Defense Health Agency Contracting Activity - Dhaca
Same awarding agency
Earlier notices in this NAICS code
Posted before this notice, open and closed
Prepare for this forecast
Research this forecast and prepare for the solicitation
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 750+ contractors already using CLEATUS
